The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Petrova N.N.

Saint-Petersburg State University

Sexual dysfunction on the background of antidepressant therapy

Authors:

Petrova N.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(11‑2): 115‑121

DOI: 10.17116/jnevro2023123112115

Read: 20936 times

Download PDF (RU)
Contact the author
Table of contents

SEXUAL DYSFUNCTION ON THE BACKGROUND OF ANTIDEPRESSANT THERAPY
SEXUAL DYSFUNCTION ON THE BACKGROUND OF ANTIDEPRESSANT THERAPY

To cite this article:

Petrova NN. Sexual dysfunction on the background of antidepressant therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(11‑2):115‑121. (In Russ.)
https://doi.org/10.17116/jnevro2023123112115

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Stress and sleep: Neurobiological aspe­cts and modern options of inso­mnia therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):14-21
Factors of depression acco­rding to acti­graphy in the fall season. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):27-32
Cognitive impairment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73
Characteristics, treatment features and in-hospital mortality of patients with myocardial infa­rction over 75 years old in Russia acco­rding to the REGION-IM regi­stry. Russian Cardiology Bulletin. 2025;(1):22-38
Pharmacological treatment and prevention of ischemia-reperfusion syndrome in percutaneous coro­nary inte­rvention. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):191-200
Influence of griseofulvin on inte­stinal microbiota in the treatment of microsporia in rural children. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):185-190
The state of mental health of migrant workers and citi­zens of the Russian Fede­ration: A comparative analysis as illu­strated by the Moscow region. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):95-101
Postoperative peri­tonitis: epidemiology, diagnosis, surgical treatment and prognosis. Piro­gov Russian Journal of Surgery. 2025;(6):104-111
Identification of depression biomarkers: Prospects for use in clinical practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):51-55
Early diagnosis and effe­ctive therapy of diabetic poly­neuropathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):62-68
Abstract:

The review is devoted to the problem of sexual dysfunction caused by taking antidepressants. Sexual dysfunction is widespread, but it is not reported, and its impact on the quality of life and compliance of patients is underestimated. Partly because of its bidirectional association with depression, sexual dysfunction is difficult to diagnose. Possible mechanisms and risk factors associated with sexual dysfunction in patients with depression are considered. The data on the frequency of sexual dysfunction with the use of various antidepressants are given. Therapeutic strategies for sexual dysfunction associated with taking antidepressants are described. The advantages of agomelatin as an antidepressant associated with a low risk of sexual side effects are emphasized.

Keywords:

sexual dysfunction
depression
antidepressants
agomelatine
management strategies
treatment

Authors:

Petrova N.N.

Saint-Petersburg State University

Received:

16.10.2023

Accepted:

03.11.2023

Close metadata

References:

  1. International Classification of Diseases 10 revision (ICD-10). (In Russ.). https://mkb-10.com/index.php?pid=4048
  2. Clayton AH, El Haddad S, Iluonakhamhe J-P, et al. Sexual dysfunction associated with major depressive disorder and antidepressant treatment. Expert Opinion on Drug Safety. 2014;13(10):1361-1374. https://doi.org/10.1517/14740338.2014.951324
  3. Rosenberg KP, Bleiberg KL, Koscis J, Gross C. A Survey of Sexual Side Effects Among Severely Mentally Ill Patients Taking Psychotropic Medications: Impact on Compliance. Journal of Sex & Marital Therapy. 2003;29(4):289-296.  https://doi.org/10.1080/00926230390195524
  4. Rothmore J. Antidepressant-induced sexual dysfunction. Med J Aust. 2020;212(7):329-334.  https://doi.org/10.5694/mja2.50522
  5. Montejo AL, Montejo L, Baldwin DS. The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management. World Psychiatry. 2018;17(1):3-11.  https://doi.org/10.1002/wps.20509
  6. Kennedy SH, Rizvi S. Sexual dysfunction, depression, and the impact of antidepressants. J Clin Psychopharmacol. 2009;29(2):157-164.  https://doi.org/10.1097/JCP.0b013e31819c76e9
  7. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry. 2001;62(suppl 3):10-21. 
  8. Angst J. Sexual problems in healthy and depressed persons. Int Clin Psychopharmacol. 1998;13:S1-4. 
  9. Lorenz T, Rullo J, Faubion S. Antidepressant-induced female sexual dysfunction. Mayo Clin Proc. 2016;91:1280-1286.
  10. Baldwin D, Bridgman K, Buis C. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine. J Psychopharmacol. 2006;20:91-96. 
  11. Baldwin D, More RA, Brlley M. Resolution of sexual dysfunction during acute treatment of major depression with milnacipran. Hum Psychopharmacol. 2008;23:527-532. 
  12. Clayton AH, Reddy S, Focht K, et al. An evaluation of sexual functioning in employed outpatients with major depressive disorder treated with desvenlafaxine 50 mg or placebo. J Sex Med. 2013;10:768-776. 
  13. Gartlehner G, Hansen RA, Morgan LC, et al. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis. Ann Intern Med. 2011;155:772-785. 
  14. Haack S, Seeringer A, Thürmann PA, Becker T, Kirchheiner J. Sex-specific differences in side effects of psychotropic drugs: genes or gender? Pharmacogenomics. 2009;10(9):1511-1526. https://doi.org/10.2217/pgs.09.102
  15. Kennedy SH, Eisfeld BS, Dickens SE, Bacchiochi JR, Bagby RM: Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry. 2000;61:276-281. 
  16. Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry. 2002;63(4):357-366.  https://doi.org/10.4088/jcp.v63n0414
  17. Trinchieri M, Trinchieri M, Perletti G, et al. Erectile and Ejaculatory Dysfunction Associated with Use of Psychotropic Drugs: A Systematic Review. J Sex Med. 2021;18(8):1354-1363. https://doi.org/10.1016/j.jsxm.2021.05.016
  18. Montejo AL, Prieto N, Terleira A, et al. Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale. Psychopharmacol (Oxf.). 2010;24:111-120. 
  19. Corona G, Ricca V, Bandini E, et al. Selective serotonin reuptake inhibitor-induced sexual dysfunction. J Sex Med. 2009;6:1259-1269.
  20. Werneke U, Northey S, Bhugra D. Antidepressants and sexual dysfunction. Acta Psychiatr Scand. 2006;114:384-397. 
  21. Crawford AA, Lewis S, Nutt D, et al. Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals. Psychopharmacology. 2014;231:2921-2931.
  22. Hu XH, Bull SA, Hunkeler EM, et al. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry. 2004;65:959-965. 
  23. Kostyukova EG, Mosolov SN. Differentiated approach to the use of antidepressants. Modern Therapy of Mental Disorders. 2013;3:2-10. (In Russ.).
  24. Williams VSL, Baldwin DS, Hogue SL, et al. Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 European countries: a cross-sectional patient survey. J Clin Psychiatry. 2006;67:204-210. 
  25. Williams VSL, Edin HM, Hogue SL, et al. Prevalence and impact of antidepressant-associated sexual dysfunction in three European countries: replication in a cross-sectional patient survey. J Psychopharmacol. 2010;24:489-496. 
  26. Carvalho AF, Sharma MS, Brunoni AR, et al. The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature. Psychother Psychosom. 2016;85(5):270-288. 
  27. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol. 2009;29(3):259-266. 
  28. Reichenpfader U, Gartlehner G, Morgan LC, et al. Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a systematic review with network meta-analysis. Drug Saf. 2014;37(1):19-31.  https://doi.org/10.1007/s40264-013-0129-4
  29. Bergh SJ, Giraldi A. Sexual dysfunction associated with antidepressant agents. Ugeskr Laeger. 2014;176(22):325-330. 
  30. Gregorian RS, Golden KA, Bahce A, et al. Antidepressant-induced sexual dysfunction. Ann Pharmacother. 2002;36:1577-1589.
  31. Clayton AH. Female sexual dysfunction related to depression and antidepressant medications. Curr Womens Health Rep. 2002;2:182-187. 
  32. Wang SM, Han C, Bahk WM, et al. Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review. Chonnam Med J. 2018;54(2):101-112. 
  33. Williams K, Reynolds MF. Sexual dysfunction in major depression. CNS Spectr. 2006;11:19-23. 
  34. Avedisova AS. Side effects of antidepressants that impair sexual function. Psychiatry and psychopharmacotherapy named after. P.B. Gannushkina. 2005;06:322-329. (In Russ.).
  35. Montejo AL, Montejo L, Navarro-Cremades F. Sexual side-effects of antidepressant and antipsychotic drugs. Curr Opin Psychiatry. 2015;28(6):418-423.  https://doi.org/10.1097/YCO.0000000000000198
  36. Francois D, Levin AM, Kutscher EJ, Asemota B. Antidepressant-Induced Sexual Side Effects: Incidence, Assessment, Clinical Implications, and Management. Psychiatric Annals. 2017;47(3):154-160.  https://doi.org/10.3928/00485713-20170201-01
  37. Higgins A, Nash M, Lynch AM. Antidepressant-associated sexual dysfunction: impact, effects, and treatment. Drug Healthc Patient Saf. 2010;2:141-150.  https://doi.org/10.2147/DHPS.S7634
  38. Zourkova AEH. Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurence of adverse effects. Gen Physiol Biophys. 2003;22:103-113. 
  39. Zourkova A, Ceskova E, Hadasova E, et al. Links among paroxetineinduced sexual dysfunctions, gender, and CYP2D6 activity. J Sex Marital Ther. 2007;33:343-355. 
  40. Pavlidi P, Kokras N, Dalla C. Antidepressants’ effects on testosterone and estrogens: What do we know? Eur J Pharmacol. 2021;899:173998. https://doi.org/10.1016/j.ejphar.2021.173998
  41. Piazza LA, Markowitz JC, Kocsis JH, et al. Sexual functioning in chronically depressed patients treated with SSRI antidepressants: a pilot study. Am J Psychiatry. 1997;154:1757-1759.
  42. Clayton AH. Sexual function and dysfunction in women. Psychiatr Clin North Am. 2003;26:673-678. 
  43. Montgomery SA, Baldwin DS, Riley A. Antidepressant medications: a review of the evidence for drug-induced sexual dysfunction. J Affect Disord. 2002;69:119-140. 
  44. Montejo A, Majadas S, Rizvi SJ, et al. The effects of agomelatine on sexual function in depressed patients and healthy volunteers. Hum Psychopharmacol. 2011;26:537-542. 
  45. Hickie IB, Rogers NL. Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet. 2011;378:621-631. 
  46. Montejo AL, Deakin JFW, Gaillard R, et al. Better sexual acceptability of agomelatine (25 and 50 mg) compared to escitalopram (20 mg) in healthy volunteers. A 9-week, placebo-controlled study using the PRSexDQ scale. J Psychopharmacol. 2015;29(10):1119-1128. https://doi.org/10.1177/0269881115599385
  47. Kennedy SH, Rizvi S, Fulton K, et al. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol. 2008;28:329-333. 
  48. Baldwin DS, Palazzo MC, Masdrakis VG. Reduced treatment-emergent sexual dysfunction as a potential target in the development of new antidepressants. Depress Res Treat. 2013;2013:256841. https://doi.org/10.1155/2013/256841
  49. Balon R, Segraves RT. Survey of treatment practices for sexual dysfunction(s) associated with antidepressants. J SexMarital Ther. 2008;34:353-365. 
  50. Rothschild AJ. Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday. Am J Psychiatry. 1995;152:1514-1516.
  51. Baldwin DS, Foong T. Antidepressant drugs and sexual dysfunction. Br J Psychiatry. 2013;202:396-397.  https://doi.org/10.1192/bjp.bp.112.110650
  52. Waldinger MD. Psychiatric disorders and sexual dysfunction. Handb Clin Neurol. 2015;130:469-489.  https://doi.org/10.1016/B978-0-444-63247-0.00027-4
  53. Potanin SS, Tsapko DS, Ivnitskaya AY. Antidepressant-induced sexual dysfunction: prevalence and methods of correction. Psychiatry and psychopharmacotherapy. 2023;1:34-39. (In Russ.).
  54. Giatti S, Diviccaro S, Panzica G, Melcangi RC. Post-finasteride syndrome and post-SSRI sexual dysfunction: two sides of the same coin? Endocrine. 2018;61(2):180-193.  https://doi.org/10.1007/s12020-018-1593-5
  55. Peleg LC, Rabinovitch D, Lavie Y, et al. Post-SSRI Sexual Dysfunction (PSSD): Biological Plausibility, Symptoms, Diagnosis, and Presumed Risk Factors. Sex Med Rev. 2022;10(1):91-98.  https://doi.org/10.1016/j.sxmr.2021.07.001
  56. Ozmenler NK, Karlidere T, Bozkurt A, et al. Mirtazapine augmentation in depressed patients with sexual dysfunction due to selective serotonin reuptake inhibitors. Hum Psychopharmacol. 2008;23(4):321-326.  https://doi.org/10.1002/hup.929
  57. Stryjer R, Spivak B, Strous RD, et al. Trazodone for the treatment of sexual dysfunction induced by serotonin reuptake inhibitors: a preliminary open-label study. Clin Neuropharmacol. 2009;32(2):82-84.  https://doi.org/10.1097/WNF.0B013E31816D1CDC
  58. Landén M, Eriksson E, Agren H, Fahlén T. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. J Clin Psychopharmacol. 1999;19(3):268-271.  https://doi.org/10.1097/00004714-199906000-00012
  59. Fava M, Dording CM, Baker RA, et al. Effects of adjunctive aripiprazole on sexual functioning in patients with major depressive disorder and an inadequate response to standard antidepressant monotherapy: a post hoc analysis of 3 randomized, double-blind, placebo-controlled studies. Prim Care Companion CNS Disord. 2011;13:PCC.10m00994.
  60. Taylor MJ, Rudkin L, Bullemor-Day P, et al. Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database Syst Rev. 2013;(5):CD003382. https://doi.org/10.1002/14651858.CD003382.pub3
  61. Nurnberg HG, Hensley PL, Heiman JR, et al. Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial. JAMA. 2008;300(4):395-404.  https://doi.org/10.1001/jama.300.4.395
  62. Tevlin KP, Brook Yu F. Issues of choosing PDE-5 inhibitors: efficacy and safety. Experimental and Clinical Urology. 2013;(2):46-50. (In Russ.).
  63. Macias JA, Martin T, Perez V, et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther. 1997;23(3):176-194.  https://doi.org/10.1080/00926239708403923
  64. Moore BE, Rothschild AJ. Treatment of antidepressant-induced sexual dysfunction. Hosp Pract (1995). 1999;34(1):89-91,95-96.  https://doi.org/10.3810/hp.1999.01.127
  65. Montejo AL, Prieto N, de Alarcón R, et al. Management Strategies for Antidepressant-Related Sexual Dysfunction: A Clinical Approach. J Clin Med. 2019;8(10):1640. https://doi.org/10.3390/jcm8101640
  66. Quinn C, Happell B. Talking about sexuality with consumers of mental health services. Perspect Psychiatr Care. 2013;49:13-20. 
  67. Chokka PR, Hankey JR. Assessment and management of sexual dysfunction in the context of depression. Ther Adv Psychopharmacol. 2018;8(1):13-23.  https://doi.org/10.1177/2045125317720642
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.